Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) can cure previously treated high-risk chronic lymphocytic leukemia (CLL) patients if they are suitable for transplant through the graft-versus-leukemia effect. However, since the emergence of targeted therapies, the role of alloHCT for high-risk CLL is less clear. To address this question, we evaluated 108 high-risk CLL patients who underwent alloHCT from 2010 to 2018. Thirty patients from the period of 2013 to 2018 received targeted therapy prior to alloHCT. The median age for the targeted therapy cohort was 60 years (range, 30-71 years), and 20% and 73% had complete and partial remission, respectively: 76% had del(17p), 46.2% had 5 or more cytogenetic abnormalities, and 78.9% were IGHV unmutated. The median number of prior therapies was 4 (range, 1-9). With a median follow-up time of 36 months (range, 10-72 months), the 3-year overall (OS) and progression-free survival (PFS) were 87% and 69%, respectively. The 3-year cumulative incidence of nonrelapse mortality and relapse was 7% and 24%, respectively. For the control cohort of 78 patients who underwent alloHCT from 2010 to 2014 and received only chemoimmunotherapy prior to transplant, the 3-year OS and PFS were 69% and 58%, respectively. Patients treated with targeted therapy prior to alloHCT had a significantly higher number of circulating T and B cells and a lower ratio of CD4 regulatory T cells to CD4 conventional T cells early after transplant. In summary, despite multiple high-risk features, the clinical outcome of CLL patients who receive targeted therapy prior to transplant is excellent and alloHCT should be offered while the disease is under control.

• Authors: Haesook T Kim, Conner J Shaughnessy, Sharmila C Rai, Carol Reynolds, Vincent T Ho, Corey Cutler, John Koreth, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Philippe Armand, Edwin P Alyea, Joseph H Antin, Catherine J Wu, Robert J Soiffer, Jerome Ritz, Jennifer R Brown
• Journal: Blood advances (Blood Adv) Vol. 4 Issue 17 Pg. 4113-4123 (09 08 2020) ISSN: 2473-9537 [Electronic] United States
• PMID: 32882002 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 by The American Society of Hematology.

Topics

• Adult
• Aged
• Graft vs Leukemia Effect
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (therapy)
• Middle Aged
• Recurrence
• Transplantation, Homologous